Results 81 to 90 of about 51,607 (296)
Acute cerebellar syndrome can be caused by high doses of cytarabine, but it has not been described in patients with acute lymphoblastic leukemia (ALL) who received hyper-CVAD chemotherapy.
Phu Ngoc Tran, Xiao-Tang Kong
doaj +1 more source
Erythroleukaemia is a malignant neoplasm of the erythroid lineage that rarely occurs in cats. It is associated with the feline leukaemia virus (FeLV), and owing to the poor prognosis, treatment is rarely reported.
Da Sol Park+3 more
doaj +1 more source
ABSTRACT Background Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and although many patients respond to induction therapy, those who relapse or have refractory disease face a poor prognosis. Venetoclax has promising preclinical and clinical activity in ALL.
Andrew E. Place+21 more
wiley +1 more source
BackgroundTreatment of acute leukemia is challenging and long-lasting remissions are difficult to induce. Innovative therapy approaches aim to complement standard chemotherapy to improve drug efficacy and decrease toxicity.
Theresa Lowinus+10 more
semanticscholar +1 more source
ABSTRACT Treatment strategies of mature B‐cell non‐Hodgkin lymphoma (B‐NHL) have been investigated in cooperative group settings to balance toxicity and cure. A survey of institutions participating in the Children's Oncology Group (COG) was completed to assess current practice patterns for treatment strategies, supportive care, imaging, and potential ...
Jennifer A. Belsky+2 more
wiley +1 more source
BACKGROUND In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy.
T. Hughes+10 more
semanticscholar +1 more source
The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R‐CHOP) is the first‐line treatment for non‐Hodgkin lymphoma (NHL). Nine articles involving 331 patients were included in the meta‐analysis, the pooled proportion of reproductive adverse events was 22.3% (95% CI 11.4%–33.2%; p < 0.001). The findings
Rong Han+6 more
wiley +1 more source
SAMHD1 is a barrier to antimetabolite-based cancer therapies
The outcome of acute myelogenous leukemia (AML) therapy depends on the propensity of leukemic blasts to accumulate ara-CTP, the active triphosphate of cytarabine (ara-C). We identified sterile α motif and HD domain-containing protein 1 (SAMHD1) as an ara-
Sean G. Rudd+2 more
doaj +1 more source
Two‐dimensional graphene‐based nanomaterials are of significant interest in biomedical applications due to their unique physicochemical properties. Computational modeling provides useful insights into their structure and interactions with biological systems, aiding the nanoparticle design.
Alexa Kamboukos+2 more
wiley +1 more source
The current standard treatment of younger patients with mantle cell lymphoma (MCL) includes rituximab and highdose cytarabine (HD-AraC), usually followed by autologous stem cell transplantation (ASCT).
C. Visco+34 more
semanticscholar +1 more source